Free Trial
NASDAQ:AVDL

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

Avadel Pharmaceuticals logo
$8.71 -0.06 (-0.68%)
As of 11:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Key Stats

Today's Range
$8.64
$8.82
50-Day Range
$6.59
$8.84
52-Week Range
$6.38
$19.09
Volume
138,627 shs
Average Volume
1.22 million shs
Market Capitalization
$841.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.88
Consensus Rating
Buy

Company Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

AVDL MarketRank™: 

Avadel Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 382nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Avadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Avadel Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.51) to $0.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avadel Pharmaceuticals is -10.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avadel Pharmaceuticals is -10.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avadel Pharmaceuticals has a P/B Ratio of 8.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Avadel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.21% of the float of Avadel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Avadel Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving.
  • Dividend Yield

    Avadel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Avadel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.21% of the float of Avadel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Avadel Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving.
  • News Sentiment

    Avadel Pharmaceuticals has a news sentiment score of 1.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Avadel Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Avadel Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Avadel Pharmaceuticals' insider trading history.
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

Avadel, nference announce publication of data on sodium oxybate
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
See More Headlines

AVDL Stock Analysis - Frequently Asked Questions

Avadel Pharmaceuticals' stock was trading at $10.51 on January 1st, 2025. Since then, AVDL shares have decreased by 17.6% and is now trading at $8.6610.
View the best growth stocks for 2025 here
.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its earnings results on Tuesday, November, 12th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. Avadel Pharmaceuticals's revenue was up 624.6% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of Avadel Pharmaceuticals include Wealth Effects LLC (2.45%), Rhumbline Advisers (0.13%), IMC Chicago LLC and Edge Wealth Management LLC (0.03%). Insiders that own company stock include Eric J Ende, Peter J Thornton, Thomas S Mchugh, Geoffrey Michael Glass, Geoffrey Michael Glass, Linda Palczuk, Mark Anthony Mccamish and Gregory J Divis.
View institutional ownership trends
.

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX).

Company Calendar

Last Earnings
11/12/2024
Today
4/27/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVDL
Employees
70
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$19.88
High Stock Price Target
$30.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+126.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-160,280,000.00
Pretax Margin
-52.84%

Debt

Sales & Book Value

Annual Sales
$169.12 million
Price / Cash Flow
N/A
Book Value
$0.98 per share
Price / Book
8.95

Miscellaneous

Free Float
91,737,000
Market Cap
$847.44 million
Optionable
Optionable
Beta
1.52

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:AVDL) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners